BCM
ONC icon

BlueCrest Capital Management’s BeOne Medicines Ltd ONC Stock Holding History

BlueCrest Capital Management’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-15,423
Closed -$2.37M – 1856
2018
Q2 		$2.37M Buy
15,423
+8,725
+130% +$1.56M 0.06% 286
2018
Q1 		$1.13M Buy
+6,698
New +$907K 0.04% 447

Other funds holding ONC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $239B AUM 42.32% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlueCrest Capital Management's ONC Position: Q3 2018 in Review

BlueCrest Capital Management sold out of BeOne Medicines Ltd (ONC) in Q3 2018, closing a stake of 15,423 shares — an estimated $2.37M sold.

BlueCrest Capital Management first reported a position in ONC in Q1 2018 and held it in 2 quarters. The position peaked at $2.37M in Q2 2018. 144 funds tracked by Wall St. Rank hold ONC as of Q3 2018.

  • BlueCrest Capital Management reported no remaining BeOne Medicines Ltd position as of Q3 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 15,423 BeOne Medicines Ltd shares in Q3 2018, an estimated $2.37M.
  • BlueCrest Capital Management first reported a position in BeOne Medicines Ltd in Q1 2018 and held it in 2 quarters.
  • BlueCrest Capital Management's BeOne Medicines Ltd position peaked at $2.37M in Q2 2018.
  • 144 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q3 2018.

Based on BlueCrest Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.